J&J accuses divisions of Cigna of helping drain its drug copay funds, WSJ reports

Johnson & Johnson is suing Cigna, alleging that the insurer drained funds meant for patients on its costly medications by collaborating with a drug-benefit middleman.

Unsupported price hikes added $815 million to US drug spending in 2023

A report reveals five drugs accounted for $815 million in U.S. spending increases in 2023 without clinical evidence, highlighting ongoing pricing issues in the pharmaceutical industry.

U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.22%

BofA reinstates pharma coverage

Bank of America reviews 11 U.S. pharma stocks, highlighting growth potential and challenges amid patent cliffs and pricing pressures while recommending buy, neutral, and underperform ratings.

U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.17%

U.S. stocks were mixed with notable gains in tech and telecom sectors, while declines were seen in consumer goods and financials. Key stocks reached all-time highs.

J&J baby powder lawsuits stay paused amid bankruptcy trial plans

Sanofi plans to change hospital drug-discount program

Healthcare executives expect more IPOs and corporate dealmaking in 2025

Healthcare executives see increased IPOs and M&A activity in 2025, citing geopolitical risks as major concerns, with confidence improving in the sector's outlook.

Lilly sues US agency over blocking of drug-rebate program

Eli Lilly has sued HRSA for blocking its proposed drug discount changes under the federal 340B program, which aids low-income healthcare providers.

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.96%

U.S. stocks closed lower, led by losses in Technology and Consumer sectors. Notable gainers included Northern Trust and Teledyne, while losses were seen in Enphase and McDonald's.